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The SCHER Report on Non-human Primate Research —
Biased and Deeply Flawed
Jarrod Bailey and Katy Taylor
British Union for the Abolition of Vivisection, London, UK
Summary — The European Commission’s Scientific Committee on Health and Environmental Risks (SCHER)
recently issued an Opinion on the need for non-human primate (NHP) use in biomedical research, and the
possibilities of replacing NHP use with alternatives, as part of the Directive 86/609/EEC revision process.
Here, we summarise our recent complaint to the European Ombudsman about SCHER’s Opinion and the
entire consultation process. It is our opinion that the Working Group almost entirely failed to address its
remit, and that the Group was unbalanced and contained insufficient expertise. The Opinion presumed the
validity of NHP research with inadequate supporting evidence, and ignored substantial evidence against the
need for NHP research and examples of valid alternatives that could replace the use of NHPs. Because the
European Commission and others might base their approach to NHP research directly on the inquiry’s findings during the revision of Directive 86/609/EEC, the implications of a flawed analysis of the efficacy of NHP
research are extremely serious, both for animal welfare and for human health and safety. The conduct of
the SCHER inquiry, and its published Opinion, should therefore be of major and widespread concern, and
should not be given any political, scientific or legislative credibility.
Key words: alternatives, non-human primates, SCHER.
Address for correspondence: J. Bailey, British Union for the Abolition of Vivisection, 16a Crane Grove,
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Introduction
European Union (EU) Directive 86/609/EEC,
intended to ensure the protection of animals used
in scientific research and testing, is currently
undergoing a much-needed revision, more than 20
years after its adoption (1).
Of particular concern to many stakeholders is
the fact that experiments which use non-human
primates (NHPs), which have become especially
controversial in recent years, are not afforded any
specific attention under the current EU legislation.
Polls consistently show that a majority of the
British population oppose invasive and/or paincausing procedures on NHPs, whatever the proposed benefit to humans (2, 3) — an opinion that is
reflected across Europe, where, most recently, 81%
of the public were reported to agree that experiments causing pain or suffering to NHPs should be
banned (4). In 2007, the European Parliament
adopted a declaration that urged an end to experimentation on great apes and wild-caught monkeys,
and a commitment to phasing out NHP research
altogether, after the declaration was supported by
a majority of the MEPs (5).

In May 2008, building on this public and political
concern, the European Commission (EC) mandated
the Scientific Committee on Health and
Environmental Risks (SCHER) to issue an Opinion
on the need for non-human primates in biomedical
research, and the possibilities of replacing NHP use
with alternatives, as part of the Directive 86/609/
EEC revision process. Following the submission of
written evidence from stakeholders, followed by a
meeting of interested parties at which the draft
Opinion was discussed, the SCHER’s final Opinion
was published and adopted in January 2009 (6).
However, it is a widely-shared view that the
final report produced by the Committee is far from
the ‘balanced, independent and scientific’ opinion
it was purported (as well as expected and required)
to be. There are serious deficiencies in three key
areas of the report and in how it was produced. In
our view:
1. The Working Group (WG) did not adequately
address the remit requested.
2. The balance of individuals within the working
group was heavily skewed toward those individuals with expertise in animal-based research, with
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a serious absence of expertise in either specifically NHP research or the use of alternatives to
NHP research.
3. The Opinion document itself is seriously flawed,
because:
a) It presumes that non-human primate (NHP)
research is scientifically valid, relevant to,
and predictive for, humans. This default
position of validity is held with no supporting evidence other than anecdote, rhetoric
and opinion, with a lack of systematic and
comprehensive evidence borne of comprehensive, robust and critical scientific evaluation. Crucially, in our opinion, before any
assessment of the validity, scientific performance and human relevance of alternatives can be made, the imperative first step
must be to ascertain the validity, scientific
performance and human relevance of the
NHP models currently being used in
research and testing, that those alternatives
are intended to replace.
b) It contains very little of the substantial
amount of evidence against the requirement
for NHPs in research that was provided by
animal-protection stakeholders, and is
therefore unbalanced. Even if the
Committee disagreed with this evidence, it
should have been included and rebutted.
c) It clearly seeks reasons to support the use of
NHPs, and reasons against adopting alternatives. Due to the inescapable and high ethical
cost of using NHPs in research and testing,
the onus should instead have been on the
Committee to do the opposite, namely, to
explore reasons for not using NHPs and to
actively encourage the use of alternatives.
In this commentary, we present our views on the
SCHER Opinion. We outline the basis of the above
objections, present examples of the many unsubstantiated statements made by the SCHER in its
Opinion in support of NHP research, and provide
examples of serious omissions of alternative methods and evidence against NHP research that were
supplied to the Committee. We believe the entire
process was unsound from its inception to its completion, and that the resulting Opinion document
should not be given any political, scientific or legislative credibility.

Concerns Regarding the Remit
The EC requested the SCHER to issue an Opinion
on: current areas of NHP research; current possibilities for replacement; scientific timetable for a
phase-out of NHP use; opportunities for the reduc-

tion and refinement of their use in areas where no
replacement can be foreseen in the medium term,
i.e. areas deserving Three Rs investment; and
implications for biomedical research, should NHP
use be banned in the EU. Demonstrably, the
SCHER Opinion fails to consider all of these points
with any degree of significance, with the exception
of the first — areas in which NHP are currently
used. While 14 of the 25 pages of text are devoted
to this first topic, scant attention is given to the
others and, most critically, the implications of a
ban on NHP use are not addressed at all.

Current possibilities for replacement
The vast subject of alternatives to NHP research is
tackled in just 3.5 pages of the Opinion, with the
first half-page constituting a position statement in
support of animal models. There is no evidence of a
literature review regarding the status of alternative methods, nor of any consultation with the EC’s
own experts via the European Centre for the
Validation of Alternative Methods (ECVAM).

Consideration of the concept of ‘replacement’
Crucially, the WG has neither defined ‘replacement’, nor examined in any detail what is actually
required of a replacement method. It clearly
expects any alternative to wholly and directly substitute for the use of NHPs — an approach that is
not only naïve, but is out of touch with how those
that research and promote alternative methods
view their purpose or utility.
A broader approach recognises that alternatives
can allow scientific objectives to be met without
direct ‘like-for-like’ replacement. For example,
alternative strategies can increase the availability
of human organs for transplantation, obviating the
use of animal organs in xenotransplantation. This
broader approach requires researchers to ask,
“What information do I need to solve this problem?”
rather than “How do I do what I want to do without using NHPs?” It is clear that the former question is more conducive to identifying methods that
would avoid NHP use. Indeed, this approach is
reflected in the wording of Directive 86/609/EEC
itself, in Article 7(2): “An experiment shall not be
performed if another scientifically satisfactory
method of obtaining the result sought, not entailing the use of an animal, is reasonably and practicably available.” (1).
This concept appears not to be recognised by the
WG, and this is reflected in its inadequate analysis
of the current and future situation with regard to
replacement. Actual opportunities for replacement
are rapidly dismissed in the Opinion with no substantiation; for example, “The total replacement of
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animals, including NHPs in testing for safety, is
not possible based on present knowledge” (p. 22).

Examples of promising alternatives disregarded
by the WG
Many papers detailing work that can replace
NHPs in a multitude of different fields were supplied to the Committee, but were disregarded. For
example, in the SCHER Opinion:
1. In the field of Safety Testing:
a) Microdosing (7, 8) is misrepresented as a
complete replacement (p. 22), and therefore
its use in detailing the pharmacokinetic (PK)
profile of a drug (replacing the use of NHPs
for this role) is completely dismissed.
b) Similarly, the US National Academy of
Sciences (NAS) report Toxicity Testing in the
21st Century (9) is dismissed entirely, as this
focused on chemicals rather than drugs.
Although there are many key aspects within
the report that can apply to pharmaceuticals, these were not investigated.
c) The use of in vitro human-based cell culture
systems for ADME/Tox screening is barely
mentioned, despite the fact that the Committee was provided with papers detailing the
predictivity of such systems (e.g. 10–12), as
well as on methods for further improving
them (for example, by the use of three-dimensional cultures [13, 14] and microfluidic chips
[15–17]).
d) Similarly, no mention is made of the promise
of functional human tissue assays that
measure physiological effects at the level of
the organ, cell, or even the gene. Such
approaches “are often superior to extrapolation from animal data” (10, 18) and could
have detected the adverse reactions caused
by Cox-2 inhibitor drugs such as Vioxx,
which caused over 320,000 heart attacks and
strokes, killing 140,000 people, despite the
cardioprotective results obtained in pre-clinical NHP tests (e.g. 19).
e) Progress that has been made in constructing
the human immune system is also not mentioned, e.g. the presence of a fully-human
modular immune in vitro construct
(MIMIC®) for the efficacy testing of potential
vaccines, developed “in response to the
recurrent failure of animal vaccine protection studies to accurately predict human
trial results.” It measures vaccine immunogenicity via induction of the memory B-cell
response — traditionally an area of high
demand for NHPs (20, 21).

429

2. In the field of Infectious Disease Research:
a) Culture systems for infectious hepatitis C
virus (HCV) in vitro now exist, enabling
human-specific research, but the extent to
which this obviates the need to infect NHPs
(22) is entirely overlooked in the Opinion (p.
24).
b) Alternatives in malaria research are dismissed, because they may not mimic the
entire ‘whole body system’, despite providing
equivalent information. For example: imaging technologies which permit the visualisation of individual malarial parasite-derived
molecules in living cells (23); human livercell cultures which permit the study of interactions between the human immune system
and the malarial parasite (24); and genetic
studies with human volunteers, which have
identified a novel P. falciparum gene
(MB2I), the product of which could be
exploited as a vaccine target, and which
have helped our understanding of how gene
expression in the parasite influences parasitic survival and pathogenesis (25, 26).
c) Genetic screens that can replace NHPs for
vaccine testing, but have inexplicably failed
to be fully implemented, such as the
MAPREC system for polio vaccine consistency batch testing (27, 28), are not even
mentioned.
3. In the field of Neuroscience Research:
a) Alternatives to NHP use, such as humanbased studies, are barely discussed, despite
the provision to the Committee of papers
demonstrating that epidemiological studies,
imaging techniques and the use of human
post-mortem brain tissue have impacted
greatly on our knowledge of causative factors, and our understanding of brain function and regeneration in Parkinson’s Disease
patients (29–31).
b) Similar papers related to the relative value
of human-based research for stroke are also
not discussed. Imaging techniques can monitor changes in the human brain following
stroke and after treatment for the condition,
and cultured human blood vessels and
human brain slices are being used to study
contributory factors to stroke, as well as
repair mechanisms and treatments (32–34).
c) Papers demonstrating that comparison of
brain activity or behaviour between healthy
and impaired volunteers can give equivalent
information to primate brain-damaging
studies, such as hippocampus damage and
memory impairment (35, 36), are also not
considered.
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d) Similarly, the use of implanted eye coils (37)
or eye tracking devices (38) in healthy
human volunteers, obviating the need for
non-invasive primate vision research, are
disregarded.
e) Opportunities for replacement in neuroscience research, with imaging technologies
such as Magnetic Resonance Imaging (MRI)
and Functional Magnetic Resonance
Imaging
(fMRI),
Positron
Emission
Tomography (PET), Transcranial Magnetic
Stimulation (TMS), are dismissed in the
Opinion with no substantiation or justification: “…fMRI studies cannot replace studies
collected with invasive microelectrode techniques; these are much more precise anatomically and temporally” (p. 24).
f) The use of invasive single-cell recording
techniques in humans undergoing surgery
is briefly mentioned (p. 18), but not with
reference to replacement. Single-neuron
recordings have been used several times in
conscious epileptic patients (e.g. 39), and
another study demonstrated that neural
responses to visual objects within the hippocampus proper are directly linked to
visual memory performance (40). The fact
that such studies are possible should seriously call into question the need, on a caseby-case basis, for invasive NHP research.
4. In the field of Xenotransplanation Research:
a) There is no discussion on obviating the
need for xenotransplantation research by
increasing the availability of human organs
for donation and reducing the incidence of
heart disease through dietary education.
b) Evidence was provided to suggest that a combination of approaches could obviate the need
for animal organs: i) The instigation of an optout ‘presumed consent’ organ donor system
has seen huge increases in organ donation
and transplantation rates in countries which
have adopted it (41, 42). A similar system of
mandated choice has produced hundreds of
thousands of new donors in Sweden, the
impact of which is further amplified, because
each donor can potentially provide several
organs (43). In addition, the use of kidneys
from ‘living donors’ has greatly increased
transplant rates in the USA and Norway, for
example (44); ii) Just under half of all heart
transplants are for cardiomyopathy, some of
which are preventable. Just under half again
are for coronary heart disease, of which the
vast majority (if not all) are preventable (45).
Around 100,000 first-time heart attacks could
be avoided each year in the USA alone, if peo-

ple cut their intake of saturated fat by just
1–3% (46).
A scientific timetable for a phase-out of NHP
use
This important section is discussed in just half a
page of the Opinion, covering four research areas.
No time-scale for replacement, in the short,
medium or long term, is provided. Genuine efforts
should have been made to evaluate the use of
NHPs by subject area, and to provide such timescales, which could have been derived according to
the current status of, and investment rates in,
alternative methods.

Opportunities for reduction and refinement
in the meantime
Reduction and refinement methods are arguably
more researched and implemented than replacement methods. Nonetheless, this section of the
Opinion is restricted to just two pages. Though a
number of refinement and reduction opportunities
are mentioned, little detail and discussion is provided, and in most cases, no reference is made to
scientific papers.

Areas of the Three Rs which deserve
investment
Given the conservative conclusions reached by the
WG regarding the Three Rs in NHP use, this section should have been much more extensive than
the half-page of very broad recommendations for
‘more research’. To be useful to policy makers and
funding bodies, detailed and clear scientific and
regulatory requirements should have been supplied, by research area, for the replacement of
NHPs — as opposed to a brief list of generic suggestions such as, “Further research in the use of
genetically altered animal models or other suitable
mammalian species in testing of vaccines and
pharmaceuticals.”

Implications of a ban on NHP use for
biomedical research
There is no specific section dealing with this crucial question. While the opinion of the WG on the
implications for biomedical research may be
inferred from their detailed coverage of the first
issues considered (areas of NHP experimentation),
this is no substitute for a thorough analysis of the
implications, in real scientific, medical and financial terms, of an immediate ban (or even a phasedin ban) on NHP research.
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Such an analysis is imperative, specifically in
terms of the number of research projects affected,
any reduction in the production of drugs, and so on.
All claims and caveats should be substantiated. A
vital part of this would be to analyse the evidence for
the utility and validity of NHP research, which the
WG completely fails to address. Examples of
research that would have provided information on
the likely implications of a ban, but that were overlooked in the Opinion, are discussed below.

Concerns Regarding the Working
Group
The balance of individuals within the working
group was heavily skewed toward those with
expertise in general animal based research, with a
perturbing absence of expertise in NHP research
and in the use of alternative methods. Nine of the
11 members were animal researchers, of which
just five were experts in primate use — the focus of
the SCHER Opinion. Neither of the SCHER committee members who were also members of the
WG, were experts in NHP use, and only four of 11
members were experts in alternative methods.
Just one was an expert specifically in the use of
alternative methods to NHP use, though this
expertise is in the refinement of animal experiments in general.
Alternatives for chemical toxicology were summarily dismissed (p. 23) as not being relevant to
the use of NHPs, yet the Chair of the WG was an
expert in this field. Absent from the WG were
experts from ECVAM and other Three Rs institutes within the EU, such as the UK NC3Rs or the
Netherlands Centre for Alternatives to Animal
Use. Indeed, we are not aware that consultation
with these expert bodies was sought, or whether
specific comments were received from them. Also
absent from the WG were external experts in alternatives such as neuroimaging and refinement, and
other experts from many Three Rs organisations
worldwide. Similarly, the make-up of its WG did
not benefit from the European Commission’s own
partnership with industry in the form of the
European Partnership for Alternative Approaches
to Animal Testing (EPAA, which has the remit to
help accelerate the development and acceptance of
new Three Rs methods in regulatory toxicology).

Omission of Crucial Evidence Against
the Efficacy and Necessity of NHP
Research
In addition to the examples of disregarded alternatives to NHP research detailed above, further evidence that the SCHER Opinion is seriously flawed
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comprises: a) unsubstantiated statements made by
the SCHER in support of NHP research; and b)
substantial evidence against NHP experimentation that the SCHER overlooked. Salient examples
of unsubstantiated statements from the Opinion
(in italics), and relevant referenced evidence that
was disregarded, include:
1. In the field of Safety Testing:
“NHPs may be more predictive for human toxicity [in reproductive toxicology].” (p. 13). No evidence whatsoever is provided in the Opinion, of
the predictive nature of NHPs for human pharmacokinetics/pharmacodynamics/safety, or for
the superiority of NHPs over non-primate
species. On the contrary, there is ample evidence to the contrary, which was supplied to the
SCHER.
For example: 34% of NHPs in regulatory
safety tests are subjected to single-dose toxicity
tests that have been discredited (47); an
International Conference on Harmonisation
(ICH) guideline admits that primate toxicology
data “can differ from humans as much as other
species” (48); NHP developmental toxicity data
correlate with human data just 50% of the time,
less even than results from more evolutionarilydistant species such as rats, hamsters and
ferrets (49); there remains “no statisticallycredible evidence” that NHP toxicology data
“contribute any predictive value, either separately or in combination” (for example, with dog
data; 50); and, for the prediction of druginduced liver injury, NHPs are less predictive
than rodents — which failed to predict up to
51% of effects in humans (51).
2. In the field of Infectious Disease Research:
“Several vaccines currently used to protect
humans against fatal infectious diseases have
been developed through studies in NHPs.” (p.
15). Not only is this claim unsubstantiated, but
also the WG confuses the use of NHPs with critical evidence of their necessity, validity and
reliability as part of the vaccine development
process. A great deal of evidence was provided
to the WG, which illustrated critical species differences affecting vaccine research and development, and even outright failures of NHP
models. HIV, hepatitis C and malaria were
specifically mentioned.
Given that no effective AIDS vaccine exists,
despite a quarter of a century of testing in
NHPs, the claims of NHPs “playing a key role in
AIDS vaccine development” (p. 15) are fallacious. Claims that SIV-infected macaques are
an important tool, ignore the lack of correlation
between pre-clinical and clinical data, as well as
evidence outlining important differences
between HIV-infected humans and SIV-infected
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macaques, including differences in virulence,
virus genetics and biochemistry, and pathology
(52–59) — as summarised by Bailey (60).
Protective and/or therapeutic vaccine responses
have been elicited in chimpanzees via many
vaccination methods. Despite the fact that more
than 85 different vaccines have been tested in
around 200 clinical trials, protection and/or significant therapeutic effects have not been
demonstrated by any vaccine to date in
humans, despite decades of effort and extensive
research funding (60).
Nor are there human vaccines for hepatitis C
or malaria, despite years of intense NHP
research. There are critical differences between
HCV infection in chimpanzees and humans that
are not noted in the Opinion, including different
rates of chronic infection and viral clearance,
and differences in pathology, such as the incidence of liver fibrosis, cirrhosis, and hepatocellular carcinoma, mother-to-infant transmission,
and immune response (summarised in 61).
Recently, the ability to culture infectious HCV
in vitro has been achieved and improved, opening new doors for human-specific research (62).
Similar differences confound malaria
research. Although chimpanzees are susceptible to the main human malaria parasite, P. falciparum, it causes only brief and moderate
parasitisation and no severe infection, and
other species differences in susceptibility to the
parasite exist, due to receptor variability (63).
There are also serious questions as to whether
the New World monkey challenge model
(NWMCM) is sufficiently relevant for humans,
as it consists of an unnatural host, challenged
by an unnatural route of administration of an
unnatural inoculum, which can result in variable infection rates and little correlation with
results in human trials (64).
3. In the field of Neuroscience Research:
“This knowledge [from basic neuroscience
research in NHPs] is useful… to understand
effects and consequences of brain and spinal
cord damage in humans and to devise therapies.” (p. 17). NHPs differ from humans in the
spatial arrangements of their spinal cord tracts,
corticospinal termination patterns within the
ventral horn differ between primates, and differences exist in the function of central pattern
generators — an important area of concern
when attempting to translate research results
from NHPs to humans (65).
“Stroke research does not use large numbers of
NHPs, but the importance of their availability
as a research tool is significant.” (p. 19). There
are signiﬁcant species-speciﬁc and even strainspeciﬁc differences in response to ischaemic
injury (66). Greater than 1,000 putative stroke

drug candidates have been tested in animals —
with no success in humans (67). NHPs have
been widely used, and it has not been established that they are superior to non-primate
species in terms of human relevance. Experts
have concluded: “Ischaemic stroke is a case
study in failed translation” (41), and “the stroke
community needs to think long and hard about
whether these animal models are financially
and ethically viable.” (68).
“Their use is considered essential in several
research programs such as on immune based diseases (e.g. multiple sclerosis), neurodegenerative
disorders (Parkinson’s, Alzheimer’s, etc), infectious diseases (HIV, Malaria, TB, Hepatitis,
SARS, etc.) and other serious diseases.” (p. 6). Our
original submissions of evidence to the SCHER
contain detailed rebuttals of this claim and its
association with all of these diseases. Some disease-specific information is discussed earlier in
this commentary. Further examples include: a)
an argument that animal models of Alzheimer’s
disease have been a failure, due to significant
confounding species differences, with very little
progress made in understanding the various
pathologies associated with the disease (69); and
b) evidence that schizophrenia has not been
reproduced experimentally in NHPs, nor have
preventive measures, diagnostic tools or treatments been developed through them (70).
4. In the field of Xenotransplanation Research:
“However, they [in vitro and rodent models] cannot replace long term studies of function in animals including NHPs.” (p. 25). The section on
the ‘Use of NHPs in Xenotransplantation’ provides no evidence to support the need for NHPs
in xenotransplantation research, nor any evidence to indicate that xenotransplantation
itself is likely to ever be clinically useful.
Although several formidable obstacles to xenotransplantation exist, the greatest is the rejection of transplanted organs. A 2005 review
concluded that no durable mechanism for the
control of hyperacute rejection has emerged,
despite enormous effort, that additional complexities relating to immune response will
undoubtedly face researchers in the future and
any progress will be slow at best, and that lack
of host survival and potential for infection
would preclude clinical trials for the foreseeable
future (71). It is therefore disappointing that
the WG was not more critical of the need for
NHP-based xenotransplantation research.

Discussion
An investigation of such gravity, with serious consequences for human health as well as the welfare
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of NHPs, should not have been so fundamentally
and seriously flawed as the SCHER inquiry. The
remit given to the SCHER was scarcely addressed;
the Working Group (WG) had a paucity of expertise in NHP research and alternative methods; and
voluminous and crucial evidence illustrating the
inefficacy of NHP research and indicative of the
power of replacement methods was ignored, resulting in a severely biased report replete with unsubstantiated claims in favour of NHP use.
The SCHER presumed the validity and human
relevance of NHP research; supporting evidence
was scant, anecdotal and opinion-based, rather
than comprehensive, systematic and scientific. The
SCHER should have ascertained the validity, scientific performance and human relevance of the
NHP models currently being used in research and
testing; instead, it sought to find flaws in proposed
alternatives. It is not acceptable for the WG to simply state that it considered all relevant evidence —
the onus was on the committee to show that it did
so, and to demonstrate its impartiality by evaluating all relevant evidence in a rigorous manner and
discussing it in the Opinion in a balanced manner.
Because the EU is basing its approach to NHP
research directly on the inquiry’s findings in the
revision to the animal experiments directive,
which is currently being considered by the
European Parliament, the implications of a flawed
analysis about the efficacy of NHP research are
extremely serious, both for animal welfare and for
human health and safety. The conduct of the
SCHER inquiry, and its published Opinion, should
therefore be of major and widespread concern and
should not be given any political, scientific or legislative credibility.
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